Pricing Log in Create free account

Candel Therapeutics, Inc. (CADL) vs 4D Molecular Therapeutics, Inc. (FDMT)

Candel Therapeutics, Inc. and 4D Molecular Therapeutics, Inc. are both Biotechnology companies. Candel Therapeutics, Inc. and 4D Molecular Therapeutics, Inc. are of similar size ($621.5M and $615.2M). 4D Molecular Therapeutics, Inc. grew revenue faster over the last twelve months: 278,712.1% against 0.00%. Candel Therapeutics, Inc. has the higher net margin (0.00% vs −194.7%) and the higher return on invested capital (0.00% vs −186.9%). Across the 17 metrics below, Candel Therapeutics, Inc. leads on 9 and 4D Molecular Therapeutics, Inc. on 8.

Valuation

Metric CADL FDMT Biotechnology median
P/E n/m n/m 10.60
P/S 5,135.81 9.41 9.40
P/B 5.09 2.12 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 3,939.74 5.70 9.02
Earnings yield (16.28%) (22.38%) (32.88%)
Free cash flow yield (8.92%) (18.01%) (23.13%)

Profitability

Metric CADL FDMT Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (214.24%) 0.00%
Net margin 0.00% (194.74%) 0.00%
Free cash flow margin 0.00% (169.51%) 0.00%
Return on equity (81.84%) (43.25%) (51.96%)
Return on assets (56.37%) (37.09%) (46.06%)
Return on invested capital 0.00% (186.91%) 0.00%

Growth

Metric CADL FDMT Biotechnology median
Revenue growth (TTM) 0.00% 278,712.12% 6.76%
EPS growth (last fiscal year) 58.62% 18.79% 29.88%
Revenue growth, 5-year CAGR — 44.32% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CADL FDMT Biotechnology median
Debt to equity 0.38 0.05 0.00
Current ratio 16.09 8.03 4.97
Net debt to EBITDA 1.53 2.52 1.01

Dividend

Metric CADL FDMT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CADL FDMT Biotechnology median
Market cap 615.21m 621.50m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack